Details of the Drug

General Information of Drug (ID: DMM0XGL)

Drug Name
Idarubicin
Synonyms
DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin
Indication
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [1]
Acute myeloid leukaemia 2A60 Approved [2]
Adult acute monocytic leukemia N.A. Approved [1]
Childhood acute megakaryoblastic leukemia N.A. Approved [1]
Leukemia N.A. Approved [1]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 497.5
Logarithm of the Partition Coefficient (xlogp) 1.9
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 5
Hydrogen Bond Acceptor Count (hbondacc) 10
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 24 mL/min/kg [4]
Elimination
3% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 22 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.42707 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.076% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 38 L/kg [4]
Chemical Identifiers
Formula
C26H27NO9
IUPAC Name
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
Canonical SMILES
C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O
InChI
InChI=1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1
InChIKey
XDXDZDZNSLXDNA-TZNDIEGXSA-N
Cross-matching ID
PubChem CID
42890
ChEBI ID
CHEBI:42068
CAS Number
58957-92-9
DrugBank ID
DB01177
TTD ID
D01XDL
VARIDT ID
DR00386
INTEDE ID
DR0852
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN ; TOP2B_HUMAN Modulator [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [7]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [8]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [9]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [9]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Gene/Protein Processing [10]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Gene/Protein Processing [10]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [11]
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Gene/Protein Processing [10]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Gene/Protein Processing [12]
Natriuretic peptides B (NPPB) OTSN2IPY ANFB_HUMAN Gene/Protein Processing [13]
Peroxisome proliferator-activated receptor delta (PPARD) OTI4WTOP PPARD_HUMAN Gene/Protein Processing [10]
Peroxisome proliferator-activated receptor gamma (PPARG) OTHMARHO PPARG_HUMAN Gene/Protein Processing [10]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Gene/Protein Processing [14]
Vitamin D3 receptor OTFC7K35 VDR_HUMAN Gene/Protein Processing [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Idarubicin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Idarubicin and Ivosidenib. Acute myeloid leukaemia [2A60] [15]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Midostaurin. Acute myeloid leukaemia [2A60] [16]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Arn-509. Acute myeloid leukaemia [2A60] [17]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Gilteritinib. Acute myeloid leukaemia [2A60] [18]
Coadministration of a Drug Treating the Disease Different from Idarubicin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sarecycline DMLZNIQ Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Sarecycline . Acne vulgaris [ED80] [19]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Oliceridine. Acute pain [MG31] [16]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Idarubicin and Ivabradine. Angina pectoris [BA40] [17]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Idarubicin and Bepridil. Angina pectoris [BA40] [16]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Idarubicin and Dronedarone. Angina pectoris [BA40] [16]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Idarubicin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [20]
Posaconazole DMUL5EW Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Posaconazole. Aspergillosis [1F20] [19]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Levalbuterol. Asthma [CA23] [21]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Idarubicin and Pirbuterol. Asthma [CA23] [22]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Idarubicin and Roflumilast. Asthma [CA23] [17]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [17]
Clarithromycin DM4M1SG Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Clarithromycin. Bacterial infection [1A00-1C4Z] [19]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Idarubicin and Sparfloxacin. Bacterial infection [1A00-1C4Z] [23]
ABT-492 DMJFD2I Minor Decreased absorption of Idarubicin due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [24]
Retigabine DMGNYIH Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Retigabine. Behcet disease [4A62] [19]
Erdafitinib DMI782S Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [25]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Eribulin. Breast cancer [2C60-2C6Y] [16]
Lapatinib DM3BH1Y Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Lapatinib. Breast cancer [2C60-2C6Y] [19]
HKI-272 DM6QOVN Moderate Decreased clearance of Idarubicin due to the transporter inhibition by HKI-272. Breast cancer [2C60-2C6Y] [19]
Tucatinib DMBESUA Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Tucatinib. Breast cancer [2C60-2C6Y] [19]
Alpelisib DMEXMYK Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Alpelisib. Breast cancer [2C60-2C6Y] [19]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [26]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [22]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [21]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Idarubicin and Indacaterol. Chronic obstructive pulmonary disease [CA22] [22]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Arformoterol. Chronic obstructive pulmonary disease [CA22] [22]
Ulipristal DMBNI20 Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Ulipristal. Contraceptive management [QA21] [19]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Sevoflurane. Corneal disease [9A76-9A78] [16]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Probucol. Coronary atherosclerosis [BA80] [16]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Idarubicin and Pasireotide. Cushing syndrome [5A70] [16]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Osilodrostat. Cushing syndrome [5A70] [17]
Ivacaftor DMZC1HS Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [19]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Clomipramine. Depression [6A70-6A7Z] [16]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [16]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Idarubicin and Deutetrabenazine. Dystonic disorder [8A02] [27]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Idarubicin and Ingrezza. Dystonic disorder [8A02] [28]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Solifenacin. Functional bladder disorder [GC50] [16]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Sunitinib. Gastrointestinal stromal tumour [2B5B] [16]
Boceprevir DMBSHMF Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Boceprevir. Hepatitis virus infection [1E50-1E51] [19]
Telaprevir DMMRV29 Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Telaprevir. Hepatitis virus infection [1E50-1E51] [19]
Daclatasvir DMSFK9V Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Daclatasvir. Hepatitis virus infection [1E50-1E51] [19]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [29]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Idarubicin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [30]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [16]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Idarubicin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [31]
BMS-201038 DMQTAGO Moderate Decreased clearance of Idarubicin due to the transporter inhibition by BMS-201038. Hyper-lipoproteinaemia [5C80] [19]
Tolvaptan DMIWFRL Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [19]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Idarubicin and Polyethylene glycol. Irritable bowel syndrome [DD91] [17]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Idarubicin and Denosumab. Low bone mass disorder [FB83] [32]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Idarubicin and Crizotinib. Lung cancer [2C25] [33]
Brigatinib DM7W94S Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Brigatinib. Lung cancer [2C25] [19]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Idarubicin and Ceritinib. Lung cancer [2C25] [16]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Idarubicin and Osimertinib. Lung cancer [2C25] [34]
Capmatinib DMYCXKL Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [19]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Idarubicin and Selpercatinib. Lung cancer [2C25] [17]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Idarubicin and Lumefantrine. Malaria [1F40-1F45] [35]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Idarubicin and Halofantrine. Malaria [1F40-1F45] [36]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Idarubicin and Hydroxychloroquine. Malaria [1F40-1F45] [37]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [17]
Ponatinib DMYGJQO Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Ponatinib. Mature B-cell lymphoma [2A85] [19]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Idarubicin and Vemurafenib. Melanoma [2C30] [16]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and LGX818. Melanoma [2C30] [38]
Lasmiditan DMXLVDT Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Lasmiditan. Migraine [8A80] [39]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Idarubicin and Panobinostat. Multiple myeloma [2A83] [40]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Idarubicin and Tecfidera. Multiple sclerosis [8A40] [41]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Idarubicin and Siponimod. Multiple sclerosis [8A40] [35]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Idarubicin and Fingolimod. Multiple sclerosis [8A40] [42]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Idarubicin and Ocrelizumab. Multiple sclerosis [8A40] [43]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Idarubicin and Ozanimod. Multiple sclerosis [8A40] [17]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Romidepsin. Mycosis fungoides [2B01] [16]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Idarubicin and Nilotinib. Myeloproliferative neoplasm [2A20] [16]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Dasatinib. Myeloproliferative neoplasm [2A20] [44]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Idarubicin and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [45]
Rolapitant DM8XP26 Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [46]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Entrectinib. Non-small cell lung cancer [2C25] [35]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Idarubicin and Levomethadyl Acetate. Opioid use disorder [6C43] [17]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Lofexidine. Opioid use disorder [6C43] [16]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Rucaparib. Ovarian cancer [2C73] [16]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Triclabendazole. Parasitic worm infestation [1F90] [16]
Istradefylline DM20VSK Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Istradefylline. Parkinsonism [8A00] [19]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Pimavanserin. Parkinsonism [8A00] [47]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Idarubicin and Macimorelin. Pituitary gland disorder [5A60-5A61] [48]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Idarubicin and Lefamulin. Pneumonia [CA40] [49]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Degarelix. Prostate cancer [2C82] [17]
ABIRATERONE DM8V75C Moderate Decreased clearance of Idarubicin due to the transporter inhibition by ABIRATERONE. Prostate cancer [2C82] [19]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Enzalutamide. Prostate cancer [2C82] [17]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Relugolix. Prostate cancer [2C82] [17]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Levomepromazine. Psychotic disorder [6A20-6A25] [16]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Idarubicin and Canakinumab. Rheumatoid arthritis [FA20] [50]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Idarubicin and Rilonacept. Rheumatoid arthritis [FA20] [50]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Idarubicin and Golimumab. Rheumatoid arthritis [FA20] [51]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Quetiapine. Schizophrenia [6A20] [16]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Aripiprazole. Schizophrenia [6A20] [35]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Idarubicin and Iloperidone. Schizophrenia [6A20] [16]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Paliperidone. Schizophrenia [6A20] [16]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Idarubicin and Amisulpride. Schizophrenia [6A20] [52]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Asenapine. Schizophrenia [6A20] [16]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Idarubicin when combined with Anthrax vaccine. Sepsis [1G40-1G41] [53]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Idarubicin and LEE011. Solid tumour/cancer [2A00-2F9Z] [16]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Idarubicin and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [16]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [17]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Pitolisant. Somnolence [MG42] [16]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [16]
Fostamatinib DM6AUHV Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [54]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Lenvatinib. Thyroid cancer [2D10] [16]
Elagolix DMB2C0E Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Elagolix. Uterine fibroid [2E86] [19]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [55]
Propafenone DMPIBJK Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Propafenone. Ventricular tachyarrhythmia [BC71] [19]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Flecainide. Ventricular tachyarrhythmia [BC71] [16]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Idarubicin and Valganciclovir. Virus infection [1A24-1D9Z] [35]
⏷ Show the Full List of 110 DDI Information of This Drug

References

1 Idarubicin FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7083).
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
8 Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia. 2008 Nov;22(11):2110-5.
9 In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology. 2004 Jun;9(3):217-21.
10 Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
11 The induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts. Cell Mol Biol Lett. 2008;13(2):182-94. doi: 10.2478/s11658-007-0045-7. Epub 2008 Apr 10.
12 A Quantitative Approach to Screen for Nephrotoxic Compounds In Vitro. J Am Soc Nephrol. 2016 Apr;27(4):1015-28. doi: 10.1681/ASN.2015010060. Epub 2015 Aug 10.
13 The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma. 2005;52(5):430-4.
14 Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
15 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
16 Canadian Pharmacists Association.
17 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
19 Multum Information Services, Inc. Expert Review Panel.
20 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
21 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
22 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
23 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
24 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
25 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
26 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
27 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
28 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
29 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
30 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
31 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
32 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
33 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
34 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
35 Cerner Multum, Inc. "Australian Product Information.".
36 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
37 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
38 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
39 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
40 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
41 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
42 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
43 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
44 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
45 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
46 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
47 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
48 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
49 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
50 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
51 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
52 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
53 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
54 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
55 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]